These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25285801)

  • 1. Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.
    Nikolousis E; Nagra S; Pearce R; Perry J; Kirkland K; Byrne J; Dignan F; Tholouli E; Gilleece M; Russell N; Littlewood T; Cook M; Peniket A; Shaw BE; Cook G; Craddock C
    Bone Marrow Transplant; 2015 Jan; 50(1):82-6. PubMed ID: 25285801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
    Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
    Medd PG; Peniket AJ; Littlewood TJ; Pearce R; Perry J; Kirkland KE; Shaw BE; Potter MN; Craddock CF; Milligan DW; Fielding AK; Marks DI; Cook G;
    Bone Marrow Transplant; 2013 Jul; 48(7):982-7. PubMed ID: 23318533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
    Nikolousis E; Robinson S; Nagra S; Brookes C; Kinsella F; Tauro S; Jeffries S; Griffiths M; Mahendra P; Cook M; Paneesha S; Lovell R; Kishore B; Chaganti S; Malladi R; Raghavan M; Moss P; Milligan D; Craddock C
    Leuk Res; 2013 May; 37(5):561-5. PubMed ID: 23395505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab in allogeneic hematopoetic stem cell transplantation.
    Poiré X; van Besien K
    Expert Opin Biol Ther; 2011 Aug; 11(8):1099-111. PubMed ID: 21702703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Mead AJ; Thomson KJ; Morris EC; Mohamedbhai S; Denovan S; Orti G; Fielding AK; Kottaridis PD; Hough R; Chakraverty R; Linch DC; Mackinnon S; Peggs KS
    Blood; 2010 Jun; 115(25):5147-53. PubMed ID: 20371745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.
    Shaw BE; Lee F; Krishnamurthy S; Byrne JL; Seedhouse C; Mayor NP; Maldonado-Torres H; Saudemont A; Marsh SG; Madrigal JA; Russell NH
    Bone Marrow Transplant; 2015 Feb; 50(2):237-43. PubMed ID: 25347010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.
    Sauter CS; Chou JF; Papadopoulos EB; Perales MA; Jakubowski AA; Young JW; Scordo M; Giralt S; Castro-Malaspina H
    Leuk Lymphoma; 2014 Dec; 55(12):2739-47. PubMed ID: 24528216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
    Willemsen L; Jol-van der Zijde CM; Admiraal R; Putter H; Jansen-Hoogendijk AM; Ostaijen-Ten Dam MM; Wijnen JT; van Kesteren C; Waaijer JL; Lankester AC; Bredius RG; van Tol MJ
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):473-82. PubMed ID: 25485863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
    Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
    Gärtner F; Hieke S; Finke J; Bertz H
    Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Blaise D; Lopez-Corral L; Vigouroux S; Craddock C; Attal M; Jindra P; Goker H; Socié G; Chevallier P; Browne P; Sandstedt A; Duarte RF; Nagler A; Mohty M
    Bone Marrow Transplant; 2014 Mar; 49(3):389-96. PubMed ID: 24419525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
    Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
    Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.